• Latest
  • Trending
  • All
  • News
  • Business
  • Lifestyle
Johnson & Johnson Acquires V-Wave For $1.7 Billion To Boost Heart Failure Treatment Portfolio‌
‌

Johnson & Johnson Acquires V-Wave For $1.7 Billion To Boost Heart Failure Treatment Portfolio‌ ‌

August 27, 2024
MICHELE STEEB: A New Chapter For America’s Homeless: Structure, Recovery, And Hope

MICHELE STEEB: A New Chapter For America’s Homeless: Structure, Recovery, And Hope

July 26, 2025
JAMES CARTER: America’s Capex Comeback

JAMES CARTER: America’s Capex Comeback

July 26, 2025
NEWT GINGRICH: Trump Boom Or Democrat Gloom

NEWT GINGRICH: Trump Boom Or Democrat Gloom

July 26, 2025
JOSH HAMMER: Grading The Second Trump Presidency, Six Months In

JOSH HAMMER: Grading The Second Trump Presidency, Six Months In

July 26, 2025
Leftist Outrage Erupts At California Plan To Stop Paying Criminal Illegals’ Legal Bills

Leftist Outrage Erupts At California Plan To Stop Paying Criminal Illegals’ Legal Bills

July 26, 2025
Mexican Border State Asks Tourists to Travel Highways Only in Daylight Hours

Mexican Border State Asks Tourists to Travel Highways Only in Daylight Hours

July 26, 2025
LARRY ELDER: Dems Rail Against Colbert’s Cancellation — Here’s Why

LARRY ELDER: Dems Rail Against Colbert’s Cancellation — Here’s Why

July 26, 2025
Estado Fronterizo Mexicano Pide a Turistas Viajar Solo de Día

Estado Fronterizo Mexicano Pide a Turistas Viajar Solo de Día

July 26, 2025
Biden-Appointed Judge Tosses Lawsuit Against Sanctuary City Chicago

Biden-Appointed Judge Tosses Lawsuit Against Sanctuary City Chicago

July 26, 2025
NEWT GINGRICH: Beyond The August Recess

NEWT GINGRICH: Beyond The August Recess

July 26, 2025
CBS Trades One 60 Minutes Liberal Insider For Another

CBS Trades One 60 Minutes Liberal Insider For Another

July 25, 2025
JENNY BETH MARTIN: No Amnesty: America’s Immigration System Must Respect The Rule Of Law

JENNY BETH MARTIN: No Amnesty: America’s Immigration System Must Respect The Rule Of Law

July 25, 2025
  • Donald Trump
  • State of the Union
  • Elon Musk
  • Tariffs
  • Congress
  • Faith
  • Immigration
Sunday, July 27, 2025
  • Login
IJR
  • Politics
  • US News
  • Commentary
  • World News
  • Faith
  • Latest Polls
No Result
View All Result
IJR
No Result
View All Result
Home FaithTap

Johnson & Johnson Acquires V-Wave For $1.7 Billion To Boost Heart Failure Treatment Portfolio‌ ‌

by Zenger
August 27, 2024 at 5:20 am
in FaithTap, News, Wire
242 10
0
Johnson & Johnson Acquires V-Wave For $1.7 Billion To Boost Heart Failure Treatment Portfolio‌
‌
491
SHARES
1.4k
VIEWS
Share on FacebookShare on Twitter

      Global healthcare giant Johnson & Johnson (J&J) announced on Tuesday that it will acquire Israeli startup V-Wave for up to $1.7 billion. V-WAVE 

Global healthcare giant Johnson & Johnson (J&J) announced on Tuesday that it will acquire Israeli startup V-Wave for up to $1.7 billion, in a strategic move by J&J to bolster its position in the fast-growing congestive heart failure market, which is projected to reach $30 billion globally by 2030.

The $1.7b. deal is the 10th biggest acquisition in Israel’s history.

It will see J&J pay $600 million upfront, with an additional $1.1 billion in potential milestone payments tied to regulatory approvals and commercial performance targets. The acquisition is expected to provide a modest boost to J&J’s earnings, contributing an estimated 24 cents per share in 2024 and 6 cents per share in 2025.

However, the true value of the deal likely lies in the long-term growth potential of V-Wave’s innovative heart failure treatment technology.

V-Wave’s flagship product, the Ventura Interatrial Shunt (IAS), is an implantable device designed to alleviate the elevated left atrial pressure that plagues patients with congestive heart failure.

 V-Wave’s flagship product, the Ventura Interatrial Shunt (IAS), is an implantable device designed to alleviate the elevated left atrial pressure that plagues patients with congestive heart failure. SASIN TIPCHAI / PIXABAY 
 V-Wave’s flagship product, the Ventura Interatrial Shunt (IAS), is an implantable device designed to alleviate the elevated left atrial pressure that plagues patients with congestive heart failure. SASIN TIPCHAI / PIXABAY 

The minimally invasive IAS procedure aims to reduce the risk of cardiovascular events and hospitalizations for those suffering from heart failure with reduced ejection fraction – a condition where the heart muscle is unable to effectively pump blood. By creating a shunt between the left and right atriums, the device helps to relieve pressure buildup in the left atrium, potentially improving patient outcomes and quality of life.

The acquisition comes at a critical time for J&J, as the company prepares to face increased competition for its blockbuster psoriasis drug Stelara, which is set to lose patent protection next year. In response, the healthcare giant has been actively pursuing mergers and acquisitions to bolster its pipeline and drive future growth.

Israel wouldn’t have earned its reputation as the Startup Nation if some of the thousands of companies that have come out of this small country hadn’t earned big bucks for their investors.

How big? Jerusalem-based Mobileye holds the title for the most lucrative acquisition of an Israeli company: $15.3 billion – that’s how much Intel paid to acquire the company in 2017.

The $1.7b. deal is the 10th biggest acquisition in Israel’s history. BRETT HONDOW / PIXABAY 
The $1.7b. deal is the 10th biggest acquisition in Israel’s history. BRETT HONDOW / PIXABAY 

“We know V-Wave well, with our relationship dating back to our original investment in the company in 2016, and we have a deep understanding of the technology and science, as well as the company’s commitment to patients,” said Tim Schmid, Executive Vice President and Worldwide Chairman of Johnson & Johnson MedTech.

Earlier this year, J&J announced the $13.1 billion acquisition of Shockwave Medical, a move aimed at expanding its cardiovascular device portfolio. The company has also recently acquired Numab’s skin disorder drug for $1.25 billion and Proteologix for $850 million.

“At V-Wave, we are dedicated to achieving our vision to help patients around the world – and we know Johnson & Johnson MedTech shares this mission,” said Dr. Neal Eigler, CEO of V-Wave.

“We look forward to continuing to build a world where cardiovascular disease is prevented, treated and cured.”

 

            Produced in association with ISRAEL21c

            Tags: U.S. NewsZenger
            Share196Tweet123
            Zenger

            Zenger

            Advertisements

            Top Stories June 10th
            Top Stories June 7th
            Top Stories June 6th
            Top Stories June 3rd
            Top Stories May 30th
            Top Stories May 29th
            Top Stories May 24th
            Top Stories May 23rd
            Top Stories May 21st
            Top Stories May 17th

            Join Over 6M Subscribers

            We’re organizing an online community to elevate trusted voices on all sides so that you can be fully informed.





            IJR

                Copyright © 2024 IJR

            Trusted Voices On All Sides

            • About Us
            • GDPR Privacy Policy
            • Terms of Service
            • Editorial Standards & Corrections Policy
            • Subscribe to IJR

            Follow Us

            Welcome Back!

            Login to your account below

            Forgotten Password?

            Retrieve your password

            Please enter your username or email address to reset your password.

            Log In
            No Result
            View All Result
            • Politics
            • US News
            • Commentary
            • World News
            • Faith
            • Latest Polls

                Copyright © 2024 IJR

            Top Stories June 10th Top Stories June 7th Top Stories June 6th Top Stories June 3rd Top Stories May 30th Top Stories May 29th Top Stories May 24th Top Stories May 23rd Top Stories May 21st Top Stories May 17th